Pharma Tech

IDWeek 2026: ISL/LEN on track to become the first once-weekly oral HIV therapy

Oct 30, 2026, 4:28 PM

Read Full Article → IDWeek 2026: ISL/LEN on track to become the first once-weekly oral HIV therapy

Translate article text

Choose a language and wait for the translated text.

At IDWeek 2026, Samir K Gupta presented a pooled analysis of the Phase III ISLEND-1 and ISLEND-2 trials evaluating once-weekly ISL/LEN in adults with virologically suppressed HIV.